Background: Acute incomplete stent apposition (ISA) can occur at the time of stent implantation. The mechanism underlying acute ISA seems to be related to procedural technique, and additional balloon angioplasty is often performed to improve ISA. The acute ISA might either resolve or persist at follow-up (late-persistent ISA). The aim of this study was to evaluate the serial change of acute ISA after everolimus-eluting stent (EES) compared with sirolimus-eluting stent (SES) between post-stenting and 10-month follow-up by using optical coherence tomography (OCT). Methods: Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial (RESET) is a prospective multicenter randomized open-label trial comparing EES with SES in Japan. A total 77 (38EES, 39SES) patients who underwent OCT in the RESET Trial between in post-stenting and 8-12 months followup were enrolled in this study. We evaluated the serial change of acute ISA after EES implantation compared with SES between post-stenting and follow-up by using OCT. We measured maximum ISA distance, ISA cross sectional area (CSA), stent CSA at maximum ISA site, and intra-stent lumen CSA. Results: Of 38 ISA observed in EES at post-stenting (SES: 39), 28 (77%) ISA were resolved (SES: 24[71%]). Although stent CSA did not change between post-stenting and follow-up, intra-stent lumen CSA (EES: 6.81 AE 1.66 mm 2 vs. 6.02 AE 1.72 mm
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Impact Background: Optical coherence tomography (OCT) can detect various types of vessel reaction immediately after stent implantation, such as stent malapposition, thrombus, prolapse, and dissection. The aim of this study was to assess how OCT findings after stenting affect on peri-procedural myocardial enzyme leakage and vessel healing at 9-month after everolimus-eluting stent (EES) implantation. Methods: A total of 59 lesions in 48 patients treated with EES who underwent post stenting and 9-month follow-up OCT were enrolled. Blood samples were drawn before and 24 hours after index procedure to assess troponin I leakage. For the post stenting analysis, quantitative assessment of abnormal intraluminal tissue (AIT) formation inside of the stent, intra-stent dissection, edge dissection, and malapposed area of the struts were performed. At 9-month, neointimal thickness, uncover and malapposed strut, unevenness of neointima (neointima unevenness score: maximum / average neointimal thickness) were calculated.
Results: AIT area and length immediately after stent implantation was positively related to troponin I leakage at 24 hours, but not affected on 9-month OCT parameters. The length of malapposed area measured by post procedure analysis was associated with average neointima unevenness score and frequency of malapposed struts at 9-month. The maximum malapposed area after stenting was associated with frequency of malapposed struts at follow up. Intra-stent and edge dissection didn't affect either troponin leak nor follow up OCT findings (Table) . Conclusions: Mass of AIT was positively related to troponin I leak, but not affected on mid-term vessel healing. Strut malapposition was associated with insufficient vessel healings at 9-month.
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Optical Background: Suboptimal stent expansion is known to correlate with future adverse cardiac events. BVS has less radial strength compared with metallic stents. With increasing use of BVS it is important to understand its expansion characteristics. OCT is an intravascular imaging modality that allows high resolution assessment of plaque morphology, composition and stent expansion. Methods: 12 patients with angina pectoris underwent OCT-guided BVS implantation. All cross-sections of each BVS were analysed at 200mm longitudinal intervals for lumen contours and plaque characteristics. Plaque type was divided into fibrous plaque (FP) or calcific plaque (CP). Each pooled plaque characteristic was divided into 2 groups based on the medians; FP area (0-4.0mm2, >¼4.01mm2), FP thickness (0-0.79mm, >¼0.8mm), FP arc angle occupied (0-184.2o, >184.3o), CP area (0-0.68mm2,>¼0.69mm2), CP thickness (0-0.48mm, >¼0.49mm), CP arc angle (0-67.6o, >¼ 67.7o) and CP depth (0-0.19mm, >¼0.2mm). Scaffold expansion index (SEI) was defined as minimum scaffold area/maximal area expressed as a percentage. Scaffold eccentricity (SE) was defined as minimum/maximum scaffold diameter. 
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